Results 121 to 130 of about 115,969,812 (153)
Some of the next articles are maybe not open access.
Comparison of tripeptidyl peptidase 1 (CLN2) measurement by fluorometry and tandem mass spectrometry
Molecular Genetics and Metabolism, 2020Z. Lukács +4 more
semanticscholar +2 more sources
Longitudinal Assessment of Atypical Tripeptidyl Peptidase 1 Enzyme Deficiency Patients
Case Medical Research, 2019semanticscholar +2 more sources
Tripeptidyl-peptidase II is an unusually large exopeptidase. The subunits (M-r = 138,000) form an active complex with an M-r > 10(6). This paper demonstrates that the complex can spontaneously dissociate in vitro into dimers which retain 1/10th of the
Birgitta Tomkinson, B Tomkinson
exaly +1 more source
Development, Evaluation and Application of Tripeptidyl-Peptidase II Sequence Signatures
Tripeptidyl-peptidase II (TPP II) is a cytosolic peptidase that has been implicated in fat formation and cancer, apparently independent of the enzymatic activity.
Pernilla Bjerling, Birgitta Tomkinson
exaly +2 more sources
Effect of Cancer Cachexia on the Activity of Tripeptidyl-Peptidase II in Skeletal Muscle
The ubiquitin-proteasome proteolytic pathway plays a major role in degradation of myofibrillar proteins in skeletal muscle during cancer cachexia. The end-product of this pathway is oligopeptides and these are degraded by the extralysomal peptidase ...
Michael J Tisdale
exaly +2 more sources
[Tripeptidyl peptidase 1 deficiency in neuronal ceroid lipofuscinosis. A novel mutation].
Voprosy meditsinskoi khimii, 2003The data on biochemical and molecular-genetic diagnostics of a hereditary lisosomal storage disease, late infantile neuronal ceroid lipofuscinosis (CLN2) are presented. The disease is associated with a hereditary deficiency of pepstatin-unsensitive peptidase--tripeptidylpeptidase 1 (TPP1)--caused by mutations in the TPP1-coding gene CLN2.
A M, Bukina +3 more
openaire +1 more source
Bioorganic & Medicinal Chemistry Letters, 2003
We have systematically explored the structure-activity relationship (SAR) for a series of compounds 2 as inhibitors of tripeptidyl-peptidase II (TPP II), a serine protease responsible for the degradation of cholecystokinin-8 (CCK-8). This SAR evaluation of the core structure 2 suggest a fairly restrictive pharmacophore for such related structures, but ...
Henry J, Breslin +6 more
openaire +2 more sources
We have systematically explored the structure-activity relationship (SAR) for a series of compounds 2 as inhibitors of tripeptidyl-peptidase II (TPP II), a serine protease responsible for the degradation of cholecystokinin-8 (CCK-8). This SAR evaluation of the core structure 2 suggest a fairly restrictive pharmacophore for such related structures, but ...
Henry J, Breslin +6 more
openaire +2 more sources
Journal of Medicinal Chemistry, 2002
Butabindide, 1, was previously reported as a potent inhibitor (IC50 = 7 nM) of the serine protease enzyme tripeptidyl peptidase II (TPPII), an endogenous protease that degrades cholecystokinin-8 (CCK-8). We found that 1 has some inherent chemical instability, yielding diketopiperazine 2 fairly readily under mimicked physiological conditions.
Henry J, Breslin +8 more
openaire +2 more sources
Butabindide, 1, was previously reported as a potent inhibitor (IC50 = 7 nM) of the serine protease enzyme tripeptidyl peptidase II (TPPII), an endogenous protease that degrades cholecystokinin-8 (CCK-8). We found that 1 has some inherent chemical instability, yielding diketopiperazine 2 fairly readily under mimicked physiological conditions.
Henry J, Breslin +8 more
openaire +2 more sources

